Abstract
SSH-BM-I is a new synthetic compound that is synthesized from Bromomelatonin by using a newly developed synthetic method. Recently, our group demonstrated that SST-VED-I-1, which has a similar chemical structure to SSHBM- I, inhibits starvation-induced apoptosis in osteoblasts. However, the effects of SSH-BM-I on apoptosis in osteoblasts have not yet been examined. Therefore, this study examined the effects of this compound on apoptosis in osteoblasts. In the present study, MC3T3-E1 mouse osteoblasts were used and apoptosis was induced by ultraviolet radiation (UV). We investigated the effect of SSH-BM-I on apoptosis by analyzing Caspase3/7 activity, translocation of Phosphatidylserine (PS), and mRNA expression levels of Bcl-2 and Bax. We found that SSH-BM-I suppressed UV-induced cell death in a dose-dependent manner, which was accompanied with the inhibition of Caspase activation and translocation of PS. Furthermore, SSH-BM-I up-regulated Bcl-2 expression and down-regulated Bax expression. These results suggest that SSH-BM-I has an inhibitory effect on apoptosis in osteoblasts through a Bcl-2 family-dependent signaling pathway.
Keywords: SSH-BM-I, Bromomelatonin, Tryptamine, Apoptosis, Bcl-2, Bax, Bax expressio, Phosphatidylserine (PS), ultraviolet radiation (UV), Rollinia mucosa, breast cancer cells, osteoblastic activity, hemocytometer, trypsinized
Letters in Drug Design & Discovery
Title: A Novel Bromomelatonin Derivative Suppresses Apoptosis with Regulating the Expression of Bcl-2 Family Genes
Volume: 8 Issue: 10
Author(s): Yoshikazu Mikami, Masanori Somei, Eri Watanabe, Nobukazu Watanabe, Tomihisa Takahashi and Masaki J. Honda
Affiliation:
Keywords: SSH-BM-I, Bromomelatonin, Tryptamine, Apoptosis, Bcl-2, Bax, Bax expressio, Phosphatidylserine (PS), ultraviolet radiation (UV), Rollinia mucosa, breast cancer cells, osteoblastic activity, hemocytometer, trypsinized
Abstract: SSH-BM-I is a new synthetic compound that is synthesized from Bromomelatonin by using a newly developed synthetic method. Recently, our group demonstrated that SST-VED-I-1, which has a similar chemical structure to SSHBM- I, inhibits starvation-induced apoptosis in osteoblasts. However, the effects of SSH-BM-I on apoptosis in osteoblasts have not yet been examined. Therefore, this study examined the effects of this compound on apoptosis in osteoblasts. In the present study, MC3T3-E1 mouse osteoblasts were used and apoptosis was induced by ultraviolet radiation (UV). We investigated the effect of SSH-BM-I on apoptosis by analyzing Caspase3/7 activity, translocation of Phosphatidylserine (PS), and mRNA expression levels of Bcl-2 and Bax. We found that SSH-BM-I suppressed UV-induced cell death in a dose-dependent manner, which was accompanied with the inhibition of Caspase activation and translocation of PS. Furthermore, SSH-BM-I up-regulated Bcl-2 expression and down-regulated Bax expression. These results suggest that SSH-BM-I has an inhibitory effect on apoptosis in osteoblasts through a Bcl-2 family-dependent signaling pathway.
Export Options
About this article
Cite this article as:
Mikami Yoshikazu, Somei Masanori, Watanabe Eri, Watanabe Nobukazu, Takahashi Tomihisa and J. Honda Masaki, A Novel Bromomelatonin Derivative Suppresses Apoptosis with Regulating the Expression of Bcl-2 Family Genes, Letters in Drug Design & Discovery 2011; 8 (10) . https://dx.doi.org/10.2174/157018011797655287
DOI https://dx.doi.org/10.2174/157018011797655287 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Insight to Colon Targeted Drug Delivery System
Drug Delivery Letters Drug Transporters and Multiple Drug Resistance in the Most Common Pediatric Solid Tumors
Current Drug Metabolism Anti-angiogenic Treatment in Metastatic Colorectal Cancer: Current Issues and Future Aims
Current Cancer Therapy Reviews Bisphenol A as a Factor in the Mosaic of Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets Using Biologic Agents in Pediatric Rheumatologic Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Epigenetic Regulators Governing Cancer Stem Cells and Epithelial- Mesenchymal Transition in Oral Squamous Cell Carcinoma
Current Stem Cell Research & Therapy Chimeric Antigen Receptor T Cells: Self-Replicating Drugs for Cancer
Current Drug Targets JAK Inhibitors: Pharmacology and Clinical Activity in Chronic Myeloprolipherative Neoplasms
Current Medicinal Chemistry Synthesis and Biological Activities of Some Novel 2-Amino-(5 or 7-Substituted- 2-Oxoindolin-3-Ylidene) Benzoxazole-5-Carbohydrazide Derivatives
Letters in Drug Design & Discovery Immunosuppressive Treatments in Acute Myocardial Infarction and Stroke
Current Pharmaceutical Biotechnology Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Induced Dyspepsia
Current Pharmaceutical Design (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry Editorial (Thematic issue: Discovering New Anticancer Activities from Old Drugs)
Current Medicinal Chemistry Digital Mammograms with Image Enhancement Techniques for Breast Cancer Detection: A Systematic Review
Current Medical Imaging Isolation of a Phytase with Distinctive Characteristics from an Edible Mushroom, Pleurotus eryngii
Protein & Peptide Letters Tumour Targeting with Systemically Administered Bacteria
Current Gene Therapy Rheumatoid Foot and Ankle Surgery
Current Rheumatology Reviews NPY and Receptors in Immune and Inflammatory Diseases
Current Topics in Medicinal Chemistry Synthetic Glycopeptides from the Mucin Family as Potential Tools in Cancer Immunotherapy
Current Cancer Drug Targets